Metagenomics Market Size, Share & Trends Analysis Report By Technology (Shotgun Sequencing, 16S Sequencing), By Product, By Workflow, By Application (Clinical Diagnostics, Environmental), By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global metagenomics market size was valued at USD 1.46 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 14.4% from 2022 to 2030. The reduced cost of sequencing is anticipated to accelerate the adoption of metagenomics in various applications. Therefore, a wide range of international and national genome projects have been introduced in recent years. For instance, in August 2022, OpGen, Inc., a personalized medicine company, announced to launch of next-generation sequencing (NGS) services under the subsidiary, Ares Genetics. The revenue growth strategy is implemented by expanding its offering in infectious diseases across the U.S. Metagenomics played a vital role in developing a vaccination for COVID-19 through sequencing technology.

Numerous players extended sequencing programs for efficient monitoring of mutation for supporting the development of effective COVID-19 vaccines. For instance, in December 2021, researchers from the University of Calgary conducted a study on the use of metagenomics workflow in the identification of COVID-19 and its variants. The study concluded that the metagenomics technique can be useful when pathogens emerge.

Similarly, in April 2020, the overall COVID-19 vaccination R&D included 115 vaccine candidates. Around 72% of vaccines were developed by private players, while 28% were as developed as collaborative projects led by academic, public sector, and other nonprofit organizations. However, by February 2022, participation by Latin American and MEA regions impacted the regional growth, owing to increasing biotech startups and rising initiatives by international players to establish a domestic manufacturing facility in the regions to facilitate the supply & distribution.

The global metagenomics industry is surging as the outcome of advancement in technology have led to a substantial decline in the cost of genome sequencing over the past few years. For instance, Illumina introduced a sequencing system with higher throughput in 2010 for around USD 10,000. The innovation and technological advancement assisted the company to bring the cost to USD 600 in 2021. As a result, an increase in the number of metagenomics studies and their usage in clinical applications for sequence analysis has been reported.

Strategic initiatives undertaken by academic institutions and companies to advance innovative technologies are anticipated to support the upward market momentum of metagenomics. For instance, in September 2022, Illumina, Inc. announced to invest in six genomics startups from the U.K., South Africa, Ireland, Israel, Indonesia, and the U.S. As of September 2022, the company has invested in 74 genomics-based startups. Along with the seed investment, access to business guidance, Illumina's sequencing reagents and systems, operational labs, and genomics expertise are offered to the startups.

Although the deteriorating pricing of sequence analysis is projected to accelerate the industry’s growth, the variable costs have a considerable impact on revenue generation. The declining cost along with improved sensitivity made metagenomics sequencing a valuable supplement to PCR-based diagnostic assays. Hence, this resulted in the increasing use of multiple metagenomics services in clinics.

Technology Insights

The shotgun sequencing segment is projected to register a substantial CAGR of 15.5% from 2022 to 2030. Numerous academic institutions and research centers are adopting technology for their genetic studies. For instance, in July 2022, an article published on the portal of Arthritis & Rheumatology stated that the background of genetics along with disease activity impacts the composition of gut microbiota. The study performed shotgun sequencing to derive the conclusion.

Whole genome sequencing, on the other hand, has projected significant growth in the industry during the forecast period. Companies are making focused efforts to expand their business operations in the clinical rare disease diagnosis space. For instance, in June 2021, Rady Children’s Institute for Genomic Medicine partnered with Pacific Biosciences for research related to whole-genome sequencing. The initiatives aim to detect possible disease-causing genetic variants and increase the solve rates of rare disorders.

Product Insights

Kits and reagents dominate the metagenomics market with the largest share of 61.26% in 2021. A variety of reagents are employed in sequencing during the experimental preparation of the sample. The market comprises established companies such as F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, and Illumina Inc. with a wide range of reagents to match the requirements in sequencing. 

On the other hand, sequencing and data analytics services are estimated to report the fastest growth. This is attributed to the increase in the adoption of sequencing leads to a higher demand for data analysis platforms. Similarly, Companies are either providing services to perform metagenomics data interpretation or introducing products in the market so that research entities are involved in clinical practice.

For instance, ArrayGen Technologies Pvt. Ltd. offers a wide range of NGS data analysis services in the field of cancer genomics, disease association studies, agriculture biotechnology, and personalized medicine. The company utilizes 454, Illumina, Ion-Torrent, SOLID, Nanopore, PacBio, and other platforms to provide services for de novo assembly of transcriptome and genome, metatranscriptome analysis, Comparative Genomics Analysis (CGA) & annotation, 16S/28S/ITS rRNA metagenomic analysis, and custom arrays for validation of NGS data.

Workflow Insights

The sequencing segment held the largest revenue share in 2021 and is expected to maintain a similar trend with the fastest CAGR. This can be attributed to the technological advancement in sequencing resulting in it becoming more cost-effective and accurate. Companies are employing sequencing methods regularly for their genetic research, which is an essential part of genetic testing. Advancements in technology have decreased the cost of sequencing by 28% yearly.

Globally, the adoption of sequencing is a significant determinant of industry growth. According to an article published in September 2022, African regions lagged in the sequencing of genomics during the initial years of COVID-19. However, owing to increased funding, more than 100,000 genomes have been sequenced from the region. Such factors are anticipated to drive growth in the coming years.

Application Insights

The environmental segment captured the highest revenue share in 2021. Metagenomics research is rapidly developing its space in agriculture and environmental protection. Metagenomics is a new technique to understand microorganisms received from a particular environment through sequencing analysis or gene screening. According to the research conducted by Capital Medical University and Peking University Ditan Teaching Hospital in December 2021, next-generation sequencing and third-generation sequencing have showcased the advantages of rapid identification of pathogenic microorganisms.

Furthermore, clinical diagnostics is the emerging application of metagenomics with the fastest CAGR during the forecast period. Along with the diagnostics of infectious diseases, the adoption of metagenomics in clinical laboratories is also increasing and various applications have been incorporated into a regular practice of clinical.  

Regional Insights

North America dominated with a share of 47.53% in 2021. This dominance can be determined by the existence of key companies in the region with an increased circulation of funds in R&D, coupled with advancements in sequencing technology. The market witnessed collaboration between companies and academic institutions and is one of the key strategies used in the region. For instance, in September 2021, the Broad Institute established a partnership with the CDC and Theiagen Genomics to accelerate support for public health labs in the U.S. The primary focus of the partnership is to enable the surveillance of pathogen genomics around the U.S.

The Asia Pacific region is anticipated to witness the fastest growth during the forecast period owing to the extensive developments by India and China in the adoption of metagenomics in numerous applications. The increasing focus on genomics and proteomics research, coupled with increasing strategic initiatives by academic institutions for innovative development in sequencing have impacted the Asia Pacific market of metagenomics with lucrative growth opportunities throughout the forecast period.

Key Companies & Market Share Insights

Numerous companies are undertaking several strategies including product discovery and development, vertical collaboration, and building a robust product portfolio via mergers and acquisitions. For instance, in February 2021, QIAGEN extended its collaboration with INOVIO Pharmaceuticals for the development of liquid biopsy-based CDx products that can deploy the NGS method to complement INOVIO's therapy, VGX-3100. VGX-3100 is an immunotherapy designed for the treatment of advanced cervical dysplasia associated with HPV. This initiative is anticipated to strengthen clinical applications of metagenomics. Some prominent players in the global metagenomics market include:

• Bio-Rad Laboratories

• Illumina, Inc.

• PerkinElmer, Inc. 

• Thermo Fisher Scientific, Inc.

• Novogene Co., Ltd.

• Promega Corporation

• QIAGEN

• Takara Bio, Inc.

• Oxford Nanopore Technologies

• F. Hoffmann-La Roche Ltd.

Metagenomics Market Report Scope

Global Metagenomics Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global metagenomics market report based on technology, product, application, workflow, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Kits & Reagents

  • Sequencing & Data Analytics Services

  • Software

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Shotgun Sequencing

  • 16S Sequencing

  • Whole Genome Sequencing

  • Others

• Workflow Outlook (Revenue, USD Million, 2018 - 2030)

  • Pre-sequencing

  • Sequencing

  • Data Analysis

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Environmental

  • Clinical Diagnostics

  • Drug Discovery

  • Biotechnology

  • Food & Nutrition

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE